The PennZone

  • Home
  • Business
  • Non-profit
  • Construction
  • Real Estate
  • Health
  • Technology
  • Travel
  • Entertainment

SafER has announced a Stage 3 clinical trial evaluating the SafER Negative Pressure System reducing aerosol emissions during bronchoscopic procedures
The PennZone/10271927

Trending...
  • "They Said It Was Impossible": This Bottle Turns Any Freshwater Source Into Ice-Cold, Purified Drinking Water in Seconds
  • TL International Group Becomes First Global Operator to Fully Migrate to Pulsant's Dedicated Car Rental Cloud
  • Deep Learning Robotics (DLRob) Announces Pre-Launch of Zero-Teach and Teach-by-Demonstration Technology for Kitting Applications
Vacuum And Mask Respiratory Shield Endo Shield Hospital Nosuction 1 Hospital Suction 1c SafER Medical Products LLC
BRANSON, Mo. - PennZone -- Bronchoscopy is known to be an aerosol generating procedure and produce plumes of microscopic particles, some of which may carry infectious airborne organisms, that can then be inhaled by medical personnel in attendance and subsequently pose a high-risk of those medical staff contracting the disease.  "Our goal since the beginning of the pandemic has been to create a safer work environment for our friends and colleagues who are exposed to dangerous pathogens when performing aerosol generating procedures, while expanding access to those life-saving procedures for our patients", said SafER Chief Medical Officer, Dr. Rick Blubaugh.

The SafER system is the world's first portable negative pressure system that utilizes HEPA filtration to capture dangerous fugitive emissions at the source – the patient.  The system has been in use since the pandemic in hospitals, ambulances, and long-term facilities around the country and can be utilized during a variety of procedures including intubation, nebulizer, CPAP or Bi-Level PAP, endoscopy, and sputum or swab collection.

More on The PennZone
  • Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • Smallville, Sailor Moon, Reno 911! Stars Added To FAN EXPO Philadelphia Lineup, May 29-31
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)

The study is randomized controlled and will take place in a 1,000-bed tertiary facility and is expected to enroll 80 patients over a 3-month period.  The goals of the study are to assess the system and the reduction of aerosol emissions produced during bronchoscopic procedures.  Results of the study are expected to be announced late this summer.

http://www.safermedicalproducts.com

Contact
Carl Baker
cbaker@safermedicalproducts.com


Source: SafER Medical Products LLC

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Cold. Clean. Anywhere. Meet FrostSkin
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • Brain Drain Unlimited Strengthens Legal Advocacy with Advanced Training from Villanova University
  • Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
  • Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
  • Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Pallet Company Partners with Internet Marketing Company
  • Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches
  • Apostle Margelee Hylton Announces the Release of Third Day Prayer
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • "Lights Off" and Laughs On: Joseph Neibich Twists Horror Tropes in Hilariously Demonic Fashion
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Beethoven: Music of Revolution and Triumph - Eroica
  • Don't Get Burned by High Heater Prices in Philly This Winter!
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Hubble Tension Solved? Study finds evidence of an 'Invisible Bias' in How We Measure the Universe
  • Boonuspart.ee Acquires Kasiino-boonus.ee to Strengthen Its Position in the Estonian iGaming Market
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies

Popular on PennZone

  • Mark Schork Selected As 'Board Observer' By Philadelphia Bar Foundation - 177
  • Michael Judkins Releases New Poetry Book, Deeper Than You Think
  • Steve Everett Jr. Named President of L.T. Hampel Corporation
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
  • NOW OPEN - New Single Family Home Community in Manalapan
  • Precision Adult Care Expands 24/7 Adult In-Home Care Services to Meet Growing Demand in the Coachella Valley
  • Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care

Similar on PennZone

  • Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
  • Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us